gist

(redirected from Gastrointestinal stromal tumour)
Also found in: Dictionary, Medical, Legal, Encyclopedia, Wikipedia.
  • noun

Synonyms for gist

Synonyms for gist

Synonyms for gist

the central meaning or theme of a speech or literary work

References in periodicals archive ?
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
Glivec(R) has been approved in the UK for the treatment of patients with the gastrointestinal cancer, KIT (CD117)-positive gastrointestinal stromal tumours (GIST), who have had surgery to remove their cancer and are at significant risk of the cancer returning.
Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.
On 24 May 2002, Glivec received a licence in the UK to treat patients with Kit (CD 117)-positive unresectable (inoperable) and/or metastatic malignant gastrointestinal stromal tumours (GISTs), a rare form of gastrointestinal cancer.
The Pan Birmingham Cancer Network will offer sunitinib (Sutent) to NHS patients being treated for advanced kidney cancer and gastrointestinal stromal tumours (GIST), a rare form of stomach and bowel cancer.
Mitotic recombination as evidence of alternative pathogenesis of gastrointestinal stromal tumours in neuroibromatosis type 1.
The summit will also focus on a selection of rare cancers in the wake of new advancements in medical management, such as chronic myeloid leukemia (CML), a cancer of the bone marrow, gastrointestinal stromal tumours (GIST), which is a rare cancer of the stomach and gut, and neuroendocrine tumors (NET), a tumor that starts in the small bowel and spreads to the heart.
Glivec (imatinib) is already recommended as a treatment for patients with gastrointestinal stromal tumours (Gist) that cannot be removed by surgery.
Paul has endured surgery to remove a massive 8lb tumour in his stomach, diagnosed as extremely rare gastrointestinal stromal tumours and has taken drug Glivec to reduce the cancer, which was only expected to extend his life by up to three years.
Initial recommendations by the National Institute for Clinical Excellence (NICE) could deny patients diagnosed with gastrointestinal stromal tumours (GISTs), a life-threatening cancer of the GI tract, access to Glivec(r) (imatinib), the only treatment currently available for this rare disease.
Full browser ?